Core Viewpoint - Jasper Therapeutics is focused on developing briquilimab, a novel antibody therapy targeting mast cell-driven diseases, with promising clinical results reported for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [1][2]. Clinical Development - Briquilimab demonstrated a complete response rate of 89% in the BEACON study for CSU patients receiving 240 mg and 360 mg single doses [2][3]. - In the open-label extension study, 73% of patients maintained a complete response at 12 weeks with 180 mg dosed every 8 weeks [3]. - The SPOTLIGHT study showed a 92% complete response rate in CIndU patients at the 180 mg dose, with rapid onset of action observed [3]. Safety and Tolerability - Briquilimab has shown a favorable safety profile, with no dose-limiting toxicities reported and adverse events being low grade and infrequent [3][4]. - Ongoing investigations are being conducted to understand the lack of UAS7 reduction in certain cohorts, with no safety signals observed that would impede further dosing [3][6]. Financial Performance - For the second quarter of fiscal 2025, Jasper reported a net loss of $26.7 million, with a basic and diluted net loss per share of $1.74 [6][10]. - Research and development expenses for the quarter were $21.2 million, while general and administrative expenses totaled $5.9 million [6][10]. Corporate Restructuring - The company implemented a workforce reduction of approximately 50% to focus resources on its urticaria programs and preserve capital [6]. - Non-mast cell focused clinical and preclinical programs have been halted to concentrate on briquilimab development [6]. Cash Position - As of June 30, 2025, Jasper had cash and cash equivalents totaling $39.5 million, down from $71.6 million at the end of 2024 [6][13].

Core Insights - Jasper Therapeutics, Inc. presented promising data from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study, showing that 100% of participants achieved a clinical response and 92% achieved a complete response [1][2][5] - The study demonstrated rapid and durable efficacy, with significant improvements observed as early as week 1, and 66% of participants achieving clinical response by week 2 [1][5][10] - Briquilimab was well tolerated, with no serious adverse events reported in the 180mg cohort, indicating a potentially differentiated safety profile [1][9][10] Study Design and Results - The SPOTLIGHT study is an open-label clinical trial evaluating briquilimab in adult participants with cold urticaria or symptomatic dermographism who are refractory to antihistamines, enrolling 27 participants across three dose cohorts: 40mg, 120mg, and 180mg [3][4] - Among the 12 participants in the 180mg cohort, 25% were diagnosed with cold urticaria and 75% with symptomatic dermographism, with a high disease burden indicated by provocation threshold testing [4][5] - Overall, 81% of participants in the study achieved a complete response, and 96% achieved either a complete or partial response [6][7] Safety and Tolerability - The mean baseline serum tryptase for the 180mg cohort was 5.1 ng/ml, with significant reductions observed, correlating with clinical responses [8] - No serious adverse events or grade 3 or higher adverse events were reported, with mild, transient drops in neutrophil counts observed in some participants [9][10] - The safety profile of briquilimab appears favorable, with low frequency and low-grade adverse events that resolved quickly [10] Company Information - Jasper Therapeutics is focused on developing briquilimab as a therapeutic for chronic mast cell diseases, including chronic spontaneous urticaria and asthma [13] - The company is conducting clinical studies to further evaluate briquilimab's efficacy and safety profile in patients with chronic urticaria and asthma [13]